ClinicalTrials.gg
RecruitingNCT07252726Updated Jul 17, 2026

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

A Phase 4 interventional study of Morning administration of CDK4/6 inhibitor and Evening administration of CDK4/6 inhibitor in Metastatic Breast Cancer and Metastatic Prostate Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.

Planned enrollment
31st of 40
50 · median 121
Started
2026
the only one that year
Phase 4
20 of 44
3 open now
Registered
44th of 44
by date

Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 31st largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2026, is one of 20 in phase 4, and was the 44th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, or all of them as a file.
02

Study summary

The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers.

Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).

03

Conditions studied

  • Metastatic Breast Cancer
  • Metastatic Prostate Cancer

Keywords

  • Chronotherapy
  • breast cancer
  • prostate cancer
  • endocrine therapy
  • metastatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohort A (Breast Cohort) Inclusion Criteria

  • Patients with hormonal receptor positive breast cancer
  • Plan to receive endocrine therapy and a CDK4/6 inhibitor (either Ribociclib or Palbociclib) in the metastatic setting
  • Age ≥18 years
  • Able to provide oral consent
  • Willing and able to complete questionnaires as per study protocol

Cohort A (Breast Cohort) Exclusion Criteria

  • Any in taking endocrine therapy and CDK4/6 inhibitor in the morning or evening
  • Plan to receive abemaciclib (as this requires twice a day dosing)

Cohort B (Prostate Cancer) Inclusion Criteria

  • Patients with metastatic castrate sensitive prostate cancer
  • Plan to receive androgen receptor pathway inhibitor (either enzalutamide, apalutamide or abiraterone acetate) in combination with androgen deprivation therapy
  • Age ≥18 years
  • Able to provide oral consent
  • Willing and able to complete questionnaires as per study protocol

Cohort B (Prostate Cancer) Exclusion Criteria

  • Any contraindication in taking androgen receptor pathway inhibitor in the morning or evening
  • Plan to receive darolutamide (as this requires twice a day dosing)
  • Plan to receive docetaxel in combination with androgen receptor pathway inhibitor
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Cohort A, Arm A: Breast Cancer Cohort, Morning Group

    Participants with metastatic breast cancer in this arm are assigned morning administration of CDK4/6 inhibitor.

    Other: Morning administration of CDK4/6 inhibitor

  • Active comparator
    Cohort A, Arm B: Breast Cancer Cohort, Evening Group

    Participants with metastatic breast cancer in this arm are assigned evening administration of CDK4/6 inhibitor.

    Other: Evening administration of CDK4/6 inhibitor

  • Active comparator
    Cohort B, Arm A: Prostate Cancer Cohort, Morning Group

    Participants with metastatic prostate cancer in this arm are assigned morning administration of ARPI.

    Other: Morning administration of ARPI

  • Active comparator
    Cohort B, Arm B: Prostate Cancer Cohort, Evening Group

    Participants with metastatic prostate cancer in this arm are assigned evening administration of ARPI.

    Other: Evening administration of ARPI

Interventions

  • OtherMorning administration of CDK4/6 inhibitor

    Morning administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant wake up time.

  • OtherEvening administration of CDK4/6 inhibitor

    Evening administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant bedtime.

  • OtherMorning administration of ARPI

    Morning administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient wake up time.

  • OtherEvening administration of ARPI

    Evening administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient bedtime.

06

What researchers measure

Primary outcomes

  1. Feasibility: accrual per site

    Feasibility will be assessed according to a combination of metrics, including the accrual of at least 25 patients per cohort in one year for a total of three sites

    Time frame: 1 year

  2. Feasibility: participation rate

    Feasibility will be assessed according to a combination of metrics, including participation rate of at least 60% among patients approached.

    Time frame: The accrual period, approximately 1 year

  3. Feasibility: number of participants who received allocated intervention

    Feasibility will be assessed according to a combination of metrics, including at least 80% of enrolled patients receive treatment as per their allocated intervention for at least 4 weeks.

    Time frame: 4 weeks

Secondary outcomes

  1. Health-related quality of life: Functional Assessment of Cancer Therapy-General

    Health-related quality of life using Functional Assessment of Cancer Therapy-General (FACT-G). Cohort A and Cohort B will answer the FACT-G. FACT-G has a score range of 0 to 108. Higher scores indicate better quality of life.

    Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  2. Health-related quality of life: Functional Assessment of Cancer Therapy-Endocrine Symptoms

    Health-related quality of life using Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES). Cohort A and Cohort B will answer the FACT-ES. FACT-ES has a score range of 0 to 184. Higher scores indicate better quality of life.

    Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  3. Health-related quality of life: Functional Assessment of Cancer Therapy-Breast

    Health-related quality of life using Functional Assessment of Cancer Therapy-Breast (FACT-B). Cohort A will complete the FACT-B. FACT-B has a score range of 0 to 148. Higher scores indicate better quality of life.

    Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  4. Health-related quality of life: Functional Assessment of Cancer Therapy-Prostate

    Health-related quality of life using Functional Assessment of Cancer Therapy-Prostate (FACT-P). Cohort B will complete the FACT-P. FACT-P has a score range of 0 to 156. Higher scores indicate better quality of life.

    Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  5. Number of changes in treatment dose

    Time frame: 5 years

  6. Number of treatment interruptions

    Time frame: 5 years

  7. Number of treatment discontinuations

    Time frame: 5 years

  8. Cohort A's adverse events of interest

    The number of participants in Cohort A that experience QTc prolongation, neutropenia, febrile neutropenia, hepatobiliary function.

    Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  9. Cohort B's adverse events of interest

    The number of participants in Cohort B that experience hypertension, hyperglycemia, rash, hypothyroidism, fatigue.

    Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  10. Adherence to treatment

    Adherence to treatment measured by the Five-Item Medication Adherence Report Scale (MARS-5 score). The MARS-5 has a range of 5-25. Higher scores indicate high adherence.

    Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  11. Participant preference in dose timing

    Participants rank their preference on a scale of 0 to 10, where 0=prefer to take treatment in the morning, 5=no preference, 10=prefer to take treatment in the evening.

    Time frame: Baseline

Other outcomes

  1. Time to second-line systemic treatment

    Time from the randomization to start of second-line systematic treatment. This is reported on the Health Care Provider (HCP) follow up questionnaire which is completed at the various timepoints outlined in the time frame.

    Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years

  2. Overall survival

    Overall survival is the time from randomization to death from any cause. Survival status (yes/no) will be checked throughout the study at the various timepoints outlined in the time frame.

    Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years, 6-years post-randomization.

  3. PSA reduction at 6 months

    Cohort B only: prostate-specific antigen reduction.

    Time frame: 6 months

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Beltran-Bless AA, Vandermeer L, Ibrahim MFK, Hutton B, Shorr R, Savard MF, Clemons M. Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes? Curr Oncol. 2021 Jul 6;28(4):2523-2528. doi: 10.3390/curroncol28040229. PubMed 34287262 ↗
  • Savard MF, Ibrahim M, Saunders D, Pond GR, Ng TL, Awan AA, Sehdev S, Alqahtani N, Vandermeer L, MacDonald F, Beltran-Bless AA, Fallowfield L, Clemons M. A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study). NPJ Breast Cancer. 2025 May 29;11(1):49. doi: 10.1038/s41523-025-00762-7. PubMed 40442096 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 13 months is below that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Nov 28, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2033
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252726
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Feb 2, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2033 (estimated)
Last update
Jul 17, 2026

Study contacts

Lisa Vandermeer, MSc
Contact
lvandermeer@ohri.ca
613-737-7700
Deanna Saunders, MSc
Contact
dsaunders@ohri.ca
613-737-7700
Marie-France Savard, MD
principal investigator · The Ottawa Hospital
Ana-Alicia Beltran-Bless, MD
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion